Abstract
At present, the main indications for leukotriene receptor antagonists (LTRA) in pediatric asthma are as add-on therapy to inhaled corticosteroids (ICS) and as initial controller therapy in children with mild asthma, especially those who cannot or will not use ICS.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have